GT Biopharma, Inc. (NASDAQ:GTBP) · earnings preview
Quarter
Q3
EPS estimate to actual
-$2.50
At a glance
Key takeaways
01GT Biopharma is scheduled to report Q3 2026 earnings on November 13 after market close with analysts expecting a loss of $2.50 per share.
02The stock trades at $3.80 with a market capitalization of $6.8 million as a healthcare company.
03Recent quarters show consistent losses exceeding expectations: Q2 missed by 50% and Q1 missed by 37.5%.
04Investors should evaluate revenue trends, margin performance, and forward guidance rather than focusing solely on the EPS figure.
Earnings Results
GT Biopharma, Inc. (NASDAQ:GTBP) is scheduled to report its Q3 earnings results on November 13, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-2.50, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at , down from a year ago.
Company Overview
The stock currently trades at $3.80 with a market capitalization of $6.8M.
Ahead of GT Biopharma, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking GT Biopharma, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.